NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD
0.0512
+0 (+3.43%)
The current stock price of PTPI is 0.0512 USD. In the past month the price decreased by -62.07%. In the past year, price decreased by -92%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 66.13 | 815.02B | ||
JNJ | JOHNSON & JOHNSON | 15.42 | 373.36B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.05 | 278.02B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 14 | 219.57B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.63B | ||
MRK | MERCK & CO. INC. | 10.45 | 200.91B | ||
SNY | SANOFI-ADR | 11.95 | 131.07B | ||
PFE | PFIZER INC | 7.32 | 129.20B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 42.71 | 99.07B | ||
GSK | GSK PLC-SPON ADR | 8.62 | 75.99B | ||
ZTS | ZOETIS INC | 25.73 | 67.93B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.15 | 47.56B |
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 21 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
PETROS PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor, Suite 570
New York City NEW YORK 10036 US
CEO: John D. Shulman
Employees: 21
Company Website: https://www.petrospharma.com/
Investor Relations: http://irdirect.net/PTPI/sec_filings
Phone: 19732420005
The current stock price of PTPI is 0.0512 USD. The price increased by 3.43% in the last trading session.
The exchange symbol of PETROS PHARMACEUTICALS INC is PTPI and it is listed on the Nasdaq exchange.
PTPI stock is listed on the Nasdaq exchange.
7 analysts have analysed PTPI and the average price target is 1.02 USD. This implies a price increase of 1892.19% is expected in the next year compared to the current price of 0.0512. Check the PETROS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
PETROS PHARMACEUTICALS INC (PTPI) has a market capitalization of 2.74M USD. This makes PTPI a Nano Cap stock.
PETROS PHARMACEUTICALS INC (PTPI) currently has 21 employees.
The Revenue of PETROS PHARMACEUTICALS INC (PTPI) is expected to decline by -29.45% in the next year. Check the estimates tab for more information on the PTPI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PTPI does not pay a dividend.
PETROS PHARMACEUTICALS INC (PTPI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.88).
The outstanding short interest for PETROS PHARMACEUTICALS INC (PTPI) is 1.55% of its float. Check the ownership tab for more information on the PTPI short interest.
ChartMill assigns a fundamental rating of 2 / 10 to PTPI. Both the profitability and financial health of PTPI have multiple concerns.
Over the last trailing twelve months PTPI reported a non-GAAP Earnings per Share(EPS) of -4.88. The EPS decreased by -48.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -144.12% | ||
ROE | -956.75% | ||
Debt/Equity | 1.58 |
ChartMill assigns a Buy % Consensus number of 83% to PTPI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 58.64% and a revenue growth -29.45% for PTPI